MGF IGF-1 EC – 5MG

$145.00

MGF IGF-1 Ec is the 24-amino-acid MGF E-domain peptide of IGF-1 Ec. Content size is 5mg, in the form of lyophilized powder. Peptides are sold for laboratory research use only.

SKU: P-MGF-IGF-1-EC

Discount per Quantity

QuantityDiscountPrice
5 - 85%$137.75
9 +10%$130.50

Out of stock

SKU: P-MGF-IGF-1-EC Category: Brand:

What Is MGF IGF-1 Ec?

MGF IGF-1 Ec is the Mechano Growth Factor (MGF) domain made of 24 amino acids, which have been cleaved from the 110 amino acids of IGF-1 Ec, as is also seen in other important molecules such as IGF-1 (70 amino acids). Thus, MGF IGF-1 Ec corresponds to the C-terminal 24 residues of the IGF-IEb/Ec pro-peptide. MGF IGF-1 Ec is one variant of the IGF-1 protein, see also MGF, and PEG-MGF.

According to research by Janssen et al, the peptide fragment does not measurably induce IGF-1 receptor tyrosine phosphorylation.(1) Instead, the peptide appears to have potential to function as an IGF-related peptide that bypasses classical IGF-1 receptor activation, exerting an anabolic potential towards a variety of cell cultures, especially muscle cells.

 

Specifications

Name MGF IGF-1 Ec
Other known names Mechano-Growth Factor, MGF-Ct24E, MGF E domain
Molecular formula C124H204N42O41S1
Molecular weight 2971.99 g/mol
Synthesis Solid-phase peptide synthesis, US
Form Lyophilized powder
Amount per vial 5 mg
Storage −20 °C, dry, protected from light
SKU P-MGF-IGF-1-EC

 

What Does Research Show About MGF IGF-1 Ec?

What Do Studies Report About Muscle Cell Hypertrophy?

Key finding: In intestinal smooth muscle cells, synthetic MGF phosphorylated Erk5 and MEF2C and raised the smooth muscle-specific proteins α-smooth muscle actin, γ-smooth muscle actin and smoothelin; blocking Erk5 or silencing MEF2C prevented both the gene expression and the hypertrophy.(2)

Most of the research on MGF IGF-1 Ec fragments revolved around muscle cells. One of the most important experiments on the peptide was conducted by Li et al., and suggests that the peptide apparently supports muscle cell hypertrophy.(2) Interestingly, it appears to achieve that by activating Erk5 and Erk1/2 while only weakly and transiently engaging Akt, and it may do so without detectable IGF-1 receptor tyrosine phosphorylation.(1) This profile suggests potential implications of the peptide in studies conducted in laboratory settings aiming to dissect noncanonical, Erk5-centered pathways downstream of IGF-1-derived products, separate from the typical IGF-1–Akt proliferative axis.

Li et al. also suggest that in cultured intestinal smooth muscle cells, the peptide may promote an increase in cell volume and total protein content, without stimulating DNA synthesis. This contrasts with IGF-1, which drives proliferation and reduces average cell volume. Because the researchers comment that “Erk5 inhibition or MEF2C siRNA blocked smooth muscle-specific gene expression and hypertrophy induced by synthetic MGF”, the peptide may support laboratory study Erk5–MEF2C–dependent transcriptional programs. Future research may interact with the peptide for studying smooth muscle–specific genes such as α-smooth muscle actin, γ-actin, and smoothelin, all of which appear upregulated by MGF IGF-1 Ec in a MEF2C-dependent manner.

How May MGF IGF-1 Ec Affect Muscle Cell Aging?

Key finding: In primary muscle cell cultures, the MGF-24aa-E peptide extended the proliferative life span and delayed senescence of satellite cells from neonatal and young adult models, but not from old adult models, and increased hypertrophy with fewer reserve cells in all of the cultures.(3)

Kandalla et al. also suggest that MGF IGF-1 Ec may act as a modulator of cellular aging in muscle cells. In myoblasts derived from young satellite cells, repeated short exposures to MGF IGF-1 Ec seemed to mitigate cellular aging for longer in the cell cultures observed in the study.(3) The exposed cells were able to go through slightly more rounds of division, and, importantly, a larger share of them were still actively dividing even after many cycles of growth. In contrast, the control cells largely stopped dividing at that stage.

These findings fit with the idea that MGF IGF-1 Ec may briefly interact with the cell-cycle machinery in a way that is at least partly similar to IGF-1 and may interact with stress-response pathways that control when cells permanently stop dividing. However, the authors stress that any interaction with cellular lifespan is modest rather than dramatic.

In older muscle cells, MGF IGF-1 Ec did not prolong the period during which cells may keep dividing and may even have accelerated the decline in their division activity. This cellular age-dependent difference in response suggests that MGF IGF-1 Ec may be a helpful tool for experimentally comparing more aged cells versus less aged cellular senescence programs under the same culture conditions.

What Was Studied in Muscle Fibrosis?

Key finding: In a mouse model of muscle contusion with macrophage depletion, MGF did not improve muscle fiber regeneration, but it reduced fibrosis and lowered the expression of inflammatory cytokines, chemokines, the oxidative stress factor gp91phox and several matrix metalloproteinases.(4)

Another team of researchers led by Liu et al. suggests that the peptide may reduce histological fibrosis and lower early expression of collagen I and III.(4) This suggests the peptide may have an anti-fibrotic potential in injured muscle cells. In parallel, MGF IGF-1 Ec appeared to decrease “the expression of muscle [cell] inflammatory cytokines (TNF-α, IFN-γ, IL-1β, and TGF-β), chemokines (CCL2, CCL5, and CXCR4), oxidative stress factors (gp91phox) and matrix metalloproteinases (MMP-1, MMP-2, MMP-9, MMP-10, and MMP-14)”, thus hinting at diminished NADPH oxidase–related oxidative stress, though MGF "did not exert a protective effect on muscle fiber regeneration”.

The researchers suggested that the peptide may have also altered the expression of several MMPs involved in extracellular matrix turnover. Taken together, the research by Liu et al suggests that the MGF IGF-1 Ec fragment may prove to be a relevant laboratory tool to investigate and possibly modulate the balance between muscular tissue repair and fibrotic scarring.

How May MGF IGF-1 Ec Affect Cell Survival?

Key finding: MGF peptide released over two weeks from hydrogel microrods increased the migration of mesenchymal stem cells about 1.7-fold and protected neonatal rat ventricular myocytes from hypoxia-induced apoptosis, with about a twofold rise in Bcl-2.(5)

Experiments by Doroudian et al. have also explored MGF IGF-1 Ec as a potential modulator of cellular death.(5) According to researchers, the anti-apoptotic potential of the peptide was clear in the mammalian myocyte cultures exposed to low oxygen environments observed in laboratory settings. The researchers observed less DNA fragmentation and increased expression of the pro-survival gene Bcl-2 compared with hypoxic control cells. These findings suggest that the peptide may prove to be relevant experimentally as a tool to probe survival pathways in muscle cells under controlled stress.

Mechanistically, the upregulation of Bcl-2 suggests a possible engagement of intrinsic survival signaling, likely intersecting with mitochondrial pathways. Thus, the data position MGF IGF-1 Ec as a potential research reagent for reducing apoptosis in stressed muscle cells and for systematically studying how IGF-1–related peptides may promote cell survival.

What Has Been Reported About Cartilage Cells?

In a concise research review, the team of Liu et al. also investigated the potential of the MGF IGF-1 Ec fragment in other cell cultures, such as cartilage cells.(6) The data summarized by the review suggests that MGF IGF-1 Ec may support several key processes around defect zones that form when cartilage cells are mechanically overloaded or otherwise stressed.

In progenitor cell cultures, the peptide apparently potentiated TGF-β3–induced chondrogenesis, supporting Col2 and aggrecan expression while suppressing Col1. This suggests that the peptide may be a possible cofactor in systems that model matrix quality, thus stimulating hyaline rather than fibrocartilage-like cellular production. In damaged or hypoxic chondrocyte cultures, the peptide was suggested to reduce pro-fibrotic and catabolic markers (Col1, MMP1/3/13, HIF-1α) and to increase Col2, often via PI3K–Akt and MEK–ERK1/2 signaling.

The researchers posited that MGF IGF-1 Ec may also act as a factor that promotes migration of chondrocytes and mesenchymal cells under overload or severe hypoxia, apparently through RhoA–YAP activation and associated focal adhesion and cytoskeletal reorganization. This gives it potential relevance in assays of cell motility, cytoskeletal mechanics, and mechanotransduction.

Some of the data analyzed by the researchers also suggest that MGF IGF-1 Ec may dampen inflammatory signaling by apparently downregulating IL-1β, TNF-α, and TGF-β. Moreover, the peptide may mitigate apoptosis by shifting Bcl-2/Bax balance and reducing caspase-3/-8 and CHOP, making it a candidate reagent for dissecting the potential interactions between mechanical stress, ER stress/UPR, and programmed cell death in cartilage cell cultures.

What Was Reported in Bone Cells and Bone Defects?

Key finding: In rabbits with a 5-mm bone defect in the radius, five days of the MGF E peptide at the higher of two concentrations increased the rate of radiographically healed defects and the histological healing scores compared with no growth factor (p < 0.01), and in osteoblast-like cell cultures its pro-proliferative activity was 1.4 times that of IGF-1.(7)

Research by Deng et al., also suggests that MGF IGF-1 Ec may act as a potential osteoanabolic signal with a distinct profile from IGF-1.(7) The researchers conducted experiments with MC3T3-E1 osteoblast-like cells, and noted that  the peptide may stimulate proliferation more strongly than full-length MGF or IGF-1, with ~1.4-fold higher pro-proliferative activity than IGF-1. Mechanistically, the peptide may push cells into S and G2/M phases, doubling the number of cells synthesizing DNA and increasing the number of cells entering mitosis about 5-fold.

This potential was coupled with robust activation of the MAPK/ERK1/2 pathway. Once again, the researchers observed that blocking ERK almost abolished the proliferative response, whereas PI3K mitigation had minimal meaningful interaction, highlighting that MGF IGF-1 Ec may act via an ERK-dominant, IGF-1 receptor-independent mechanism.(8)

Further laboratory research in rabbits with a 5-mm defect in the radius, suggested that the peptide may increase callus formation, cortical bridging, and disappearance of the fracture line, with a subset of defects radiographically united by week 8. Histologically, the rabbit models appeared to have increased levels of lamellar bone, restored marrow cavity, higher vascularity and osteoid formation, and fewer fibroblasts compared with controls—consistent with faster, more organized bone remodeling rather than fibrous non-union.

With this in mind, the peptide may be viewed as a selective supporter of osteoblast proliferation and early bone regeneration, acting through MAPK/ERK signaling and offering a compact, synthetic tool to model or potentially augment bone cell regeneration in laboratory systems.

What Does Research Suggest About Neural Cells?

Key finding: In SH-SY5Y cells exposed to three dopaminergic neurotoxins, the 24-amino-acid C-terminal MGF peptide raised heme oxygenase-1, preserved the mitochondrial membrane potential and reduced apoptosis; blocking heme oxygenase-1 abolished that protection, and in 6-hydroxydopamine-lesioned rats the peptide reduced the loss of nigral dopamine cell bodies independently of the IGF-1 receptor.(8)

Research by Quesada et al. suggests that MGF IGF-1 Ec may support cell survival, reduce apoptotic markers, and maintain mitochondrial integrity in SH-SY5Y neuroblastoma cells found in mammalian models with mitochondrial dysfunction and increased apoptosis due to neurotoxin exposure.(8)

Mechanistically, this interaction has been linked to upregulation of heme-oxygenase-1 (HO-1), which, when mitigated, appears to negate the peptide’s protective potential. Further research has similarly suggested that MGF IGF-1 Ec may reduce loss of vulnerable neuronal populations and preserve motor performance under neurotoxic or degenerative conditions. Moreover, the peptide may mimic a stress-protective, ERK-linked stimulus in neural-like cells.

MGF IGF-1 Ec peptide is available for research and laboratory purposes only. We offer free shipping in the US for orders over $200. Please review our Terms and Conditions before ordering.

 

Frequently Asked Questions

What is MGF IGF-1 Ec?

MGF IGF-1 Ec is the 24-amino-acid C-terminal E domain of the IGF-1Ec splice variant, also called MGF-Ct24E.

How is MGF IGF-1 Ec different from full-length MGF?

They behave differently at the IGF-1 receptor: in receptor assays the short peptide produced no IGF-1 receptor activation, while full-length MGF activated it to a maximal level similar to IGF-1.

What has MGF IGF-1 Ec been studied for?

Laboratory research has examined it in smooth and skeletal muscle cells, cardiac myocytes under low oxygen, cartilage and bone cells, bone defects in rabbits and neurotoxin-exposed nerve cell lines.

Which signaling pathways are reported for it?

The published work points to ERK pathways, including Erk5 with MEF2C in smooth muscle cells and MAPK/ERK1/2 in osteoblast-like cells, rather than the IGF-1 receptor and Akt route.

How should MGF IGF-1 Ec be stored?

Lyophilized MGF IGF-1 Ec should be stored at −20 °C, dry and protected from light.

 

References:

  1. Janssen, J. A., Hofland, L. J., Strasburger, C. J., van den Dungen, E. S., & Thevis, M. (2016). Potency of Full-Length MGF to Induce Maximal Activation of the IGF-I R Is Similar to Recombinant Human IGF-I at High Equimolar Concentrations. PloS one, 11(3), e0150453. https://doi.org/10.1371/journal.pone.0150453
  2. Li, C., Vu, K., Hazelgrove, K., & Kuemmerle, J. F. (2015). Increased IGF-IEc expression and mechano-growth factor production in intestinal muscle of fibrostenotic Crohn's disease and smooth muscle hypertrophy. American journal of physiology. Gastrointestinal and liver physiology, 309(11), G888–G899. https://doi.org/10.1152/ajpgi.00414.2014
  3. Kandalla, P. K., Goldspink, G., Butler-Browne, G., & Mouly, V. (2011). Mechano Growth Factor E peptide (MGF-E), derived from an isoform of IGF-1, activates human muscle progenitor cells and induces an increase in their fusion potential at different ages. Mechanisms of ageing and development, 132(4), 154–162. https://doi.org/10.1016/j.mad.2011.02.007
  4. Liu, X., Zeng, Z., Zhao, L., Chen, P., & Xiao, W. (2019). Impaired Skeletal Muscle Regeneration Induced by Macrophage Depletion Could Be Partly Ameliorated by MGF Injection. Frontiers in physiology, 10, 601. https://doi.org/10.3389/fphys.2019.00601
  5. Doroudian, G., Pinney, J., Ayala, P., Los, T., Desai, T. A., & Russell, B. (2014). Sustained delivery of MGF peptide from microrods attracts stem cells and reduces apoptosis of myocytes. Biomedical microdevices, 16(5), 705–715. https://doi.org/10.1007/s10544-014-9875-z
  6. Liu, Y., Duan, M., Zhang, D., & Xie, J. (2023). The role of mechano growth factor in chondrocytes and cartilage defects: a concise review. Acta biochimica et biophysica Sinica, 55(5), 701–712. https://doi.org/10.3724/abbs.2023086
  7. Deng, M., Zhang, B., Wang, K., Liu, F., Xiao, H., Zhao, J., Liu, P., Li, Y., Lin, F., & Wang, Y. (2011). Mechano growth factor E peptide promotes osteoblasts proliferation and bone-defect healing in rabbits. International orthopaedics, 35(7), 1099–1106. https://doi.org/10.1007/s00264-010-1141-2
  8. Quesada, A., Micevych, P., & Handforth, A. (2009). C-terminal mechano growth factor protects dopamine neurons: a novel peptide that induces heme oxygenase-1. Experimental neurology, 220(2), 255–266. https://doi.org/10.1016/j.expneurol.2009.08.029

Related reading: MGF IGF-1 Ec peptide potential for muscle cell research and Mechano Growth Factor (MGF) peptide actions on muscular tissue, bone and cartilage cells.

Dr. Dimitar Marinov

Dimitar Marinov, MD, PhD, is a physician specializing in nutrition and dietetics and an assistant professor in the Department of Hygiene and Epidemiology at the Medical University of Varna, Bulgaria. He reviews the scientific content published by Core Peptides.

0
Your Cart
Your cart is empty